Novartis signs gene therapy deal with Voyager for US$100 million upfront
Voyager Therapeutics said on Tuesday (Jan 2) Swiss-based drugmaker Novartis would pay US$100 million upfront as part of a licensing deal to develop gene therapy candidates for genetic disorders.
Voyager, whose shares jumped more than 30 per cent in premarket trading, would be eligible to receive up to US$1.2 billion on achieving certain milestones.
The gene therapy developer would provide Novartis access to its RNA-based screening platform – which helps in rapid discovery of experimental gene therapies – and would also be eligible for tiered royalties on global sales of products developed using the platform.
The companies would collaborate to develop a pre-clinical gene therapy candidate for Huntington’s disease (HD), an inherited condition that causes nerve cells in parts of the brain to gradually break down and die.
Voyager would advance the pre-clinical development and Novartis would be responsible for all clinical studies and commercialisation for the HD candidate.
Novartis would also gain access to Voyager’s platform for discovery and development of potential gene therapies for treating spinal muscular atrophy, a group of rare genetic disorders which affect the nerve cells and cause muscle wasting and weakness.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Novartis had previously exercised an option to license novel capsids or gene therapy delivery vehicles generated from Voyager’s drug discovery platform as a potential treatment for two undisclosed neurological conditions.
Separately, Voyager is developing an investigational gene therapy to treat a neurological disease, amyotrophic lateral sclerosis, and an antibody for the Alzheimer’s disease. REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Top HSBC shareholder Ping An exploring ways to cut US$13 billion stake
Gazelle Ventures’ cash offer for No Signboard closes with 0.5022% valid acceptances
Dow briefly sprints past 40,000-mark on earnings boost, rate-cut bets
Goldman strikes US$43 billion investing deal for UPS pension funds
US: Wall Street opens nearly flat after CPI-driven rally
Blackstone to buy Priority Software stake in biggest Israel deal